Andrew Marlowe, MD
Otology & Neurotology · Sarasota, FLNPI 1215985247
Payments from drug & device makers
Across 450 payments — averaging $26.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Biohaven Pharmaceuticals, Inc.$1K
- Amgen$1K
- Sanofi$970
- Regeneron Healthcare Solutions, Inc.$784
- Pfizer$696
- plus $5K from 29 others
What the payments were for
- Travel & lodging$2612%
- Food & beverage$11,58497%
- Education$1551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 72 | $1,941 |
| Biohaven Pharmaceuticals, Inc. | 30 | $1,185 |
| Amgen | 56 | $1,060 |
| Sanofi | 28 | $970 |
| Regeneron Healthcare Solutions, Inc. | 30 | $784 |
| Pfizer | 41 | $696 |
| Merz North America, Inc. | 4 | $681 |
| Teva Pharmaceuticals USA, Inc. | 33 | $535 |
| Optinose US, Inc. | 18 | $470 |
| GSK | 16 | $385 |
| Phathom Pharmaceuticals, Inc. | 6 | $384 |
| Stryker | 4 | $350 |
| Lilly USA, LLC | 20 | $323 |
| Lundbeck LLC | 9 | $307 |
| Med-el Corporation | 4 | $291 |
| Upsher-smith Laboratories LLC | 11 | $241 |
| Novartis | 14 | $198 |
| Advanced Bionics, LLC | 10 | $178 |
| Biohaven Pharmaceutical Holding Company Ltd. | 15 | $168 |
| Sanofi-aventis U.S. LLC | 2 | $137 |
| Kerecis Limited | 1 | $137 |
| Neurent Medical Limited | 4 | $105 |
| Alk-abello, Inc | 5 | $101 |
| Acclarent, Inc | 3 | $93 |
| Vertical Pharmaceuticals, LLC | 2 | $47 |
| Photonicare Inc | 1 | $41 |
| Merck | 2 | $39 |
| Hikma Pharmaceuticals USA | 2 | $34 |
| Medtronic | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $17 |
| Ambu Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$915
- XEOMIN$657
- ASCLERA$514
- QULIPTA$503
- UBRELVY$503
- Kerecis Omega3 SurgiClose$410
- VOQUEZNA$241
- VIBRANT Soundbridge Middle Ear Implant and BONEBRIDGE System$225
- XPRESS ENT DILATION SYSTEM$156
- FIAGON NAVIGATION UNIT$156
- ENTELLUS - XPRESS ENT DILATION SYSTEM$137
- Kerecis Omega3 GraftGuide$137
- Kerecis Omega3 Marigen$137
- Xhance$135
- VYEPTI$124
- NUCALA$123
- TEPEZZA$123
- AIMOVIG$122
- DUPIXENT$122
How this compares
$12,000 in reported general payments places this provider in the 55th percentile of 25 otology & neurotology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 14 | $53,942 |
| Aimovig AutoinjectorErenumab-Aooe | 62 | $49,902 |
| QuliptaAtogepant | 19 | $28,908 |
| Nurtec OdtRimegepant Sulfate | 12 | $22,742 |
| Ipratropium Bromide | 262 | $9,172 |
| NexiumEsomeprazole Magnesium | 12 | $6,499 |
| Esomeprazole Magnesium | 34 | $3,116 |
| Pantoprazole Sodium | 174 | $2,502 |
| Ofloxacin | 68 | $1,901 |
| Fluticasone Propionate | 115 | $1,840 |
| Pilocarpine Hcl | 32 | $1,818 |
| Gabapentin | 156 | $1,557 |
| Azelastine Hcl | 58 | $1,485 |
| Dexamethasone Sodium Phosphate | 13 | $1,309 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $1,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta | $1,941 | $28,90819 claims |
| PfizerNurtec Odt | $696 | $22,74212 claims |
| Upsher-smith Laboratories LLCTopiramate | $241 | $32517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 25 otology & neurotology providers in Florida.
Other otology & neurotology in Sarasota
- Herbert SilversteinSarasota$3.5M
- Jack WazenSarasota$18K
- Seth RosenbergSarasota$3K
- Thomas BalkanyMiami$534K
- Fred TelischiMiami$111K
- Peter VolskySouth Miami$97K
- Joshua LightBoynton Beach$72K
- Simon AngeliMiami$57K
- Loren BartelsTampa$35K
- Christopher DannerTampa$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.